NEW DELHI, India--(BUSINESS WIRE)--Dec. 8, 2005--Merck & Co., Inc. and PATH today announced that the two organizations will work together to conduct clinical studies of Merck's investigational rotavirus vaccine, ROTATEQ(TM) (rotavirus vaccine, live, oral, pentavalent), in some of the world's developing nations. The trials are one step in the process of making a rotavirus vaccine available in these regions as quickly as possible. The announcement was made at the Global Alliance for Vaccines and Immunization (GAVI) partners meeting.
